Grown Rogue International (GRUSF) Net Income towards Common Stockholders Growth (3y) (2012 - 2023)
Grown Rogue International (GRUSF) Net Income towards Common Stockholders Growth (3y) (2012 - 2023) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 51.28% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 2.94% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -70.54% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 4.50% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | -7.75% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 66.11% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -17.90% |
| 10 | Grown Rogue International | 99.97 Mn | 86.26 Mn | 3.96 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Oct 31, 2023 | -293.69% |
| Jul 31, 2023 | 31.17% |
| Apr 30, 2023 | 32.39% |
| Jan 31, 2023 | 37.14% |
| Jan 31, 2022 | 55.50% |
| Jul 31, 2021 | 66.58% |
| Apr 30, 2021 | -24.97% |
| Jan 31, 2021 | -18.14% |
| May 31, 2018 | 6,628.88% |
| Feb 28, 2018 | -10,675.75% |
| Nov 30, 2017 | 16,691.54% |
| May 31, 2017 | 97.06% |
| Aug 31, 2016 | 4,437.73% |
| May 31, 2016 | 158.43% |
| Feb 29, 2016 | 99.09% |
| May 31, 2015 | 98.23% |
| Feb 28, 2015 | 25.99% |
| Nov 30, 2014 | 25.99% |
| Aug 31, 2014 | -47.44% |
| May 31, 2014 | 70.76% |